A citation-based method for searching scientific literature

Céline Phan, Nathalie Beneton, Juliette Delaunay, Ziad Reguiai, Claire Boulard, Anne-Claire Fougerousse, Elisa Cinotti, Marco Romanelli, Laure Mery-Bossard, Domitille Thomas-Beaulieu, Josiane Parier, François Maccari, Jean-Luc Perrot, Mireille Ruer-Mulard, Marie Bastien, Edouard Begon, Mahtab Samimi, Caroline Jacobzone, Nathalie Quiles-Tsimaratos, Vincent Descamps, Maud Steff, Paul Bilan, Annie Vermersch-Langlin, Mathilde Kemula, Emmanuelle Amazan, Ingrid Kupfer-Bessaguet, Anne-Caroline Cottencin, Francesca Prignano, Bulai Livideanu, Jeremy Gottlieb, Alain Beauchet, Emmanuel Mahé. Acta Derm Venereol 2020
Times Cited: 7







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Stefano Piaserico, Andrea Conti, Francesco Lo Console, Clara De Simone, Francesca Prestinari, Annamaria Mazzotta, Giulio Gualdi, Claudio Guarneri, Stefania Borsari, Nicoletta Cassano. Acta Derm Venereol 2014
57
57

Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review.
Vijay Kumari Sandhu, Arvin Ighani, Patrick Fleming, Charles W Lynde. J Cutan Med Surg 2020
13
57

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt. Drugs Aging 2018
31
57

Managing moderate-to-severe psoriasis in the elderly.
Nicola Balato, Cataldo Patruno, Maddalena Napolitano, Angela Patrì, Fabio Ayala, Raffaele Scarpa. Drugs Aging 2014
39
57

Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
C Medina, G Carretero, C Ferrandiz, E Dauden, F Vanaclocha, F J Gómez-García, E Herrera-Ceballos, P De la Cueva-Dobao, I Belinchón, J L Sánchez-Carazo,[...]. J Eur Acad Dermatol Venereol 2015
34
57

Elderly psoriatic patients under biological therapies: an Italian experience.
F Ricceri, F Bardazzi, A Chiricozzi, P Dapavo, F Ferrara, C Mugheddu, M Romanelli, F Rongioletti, F Prignano. J Eur Acad Dermatol Venereol 2019
17
42

Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Maria Esposito, Alessandro Giunta, Annamaria Mazzotta, Arianna Zangrilli, Graziella Babino, Mauro Bavetta, Roberto Perricone, Sergio Chimenti, Maria Sole Chimenti. Dermatology 2012
54
42

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Alan Menter, Kenneth B Gordon, Craig L Leonardi, Yihua Gu, Orin M Goldblum. J Am Acad Dermatol 2010
107
42

Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation.
Ivan S Grozdev, Abby S Van Voorhees, Alice B Gottlieb, Sylvia Hsu, Mark G Lebwohl, Bruce F Bebo, Neil J Korman. J Am Acad Dermatol 2011
36
42

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
Mitsuha Hayashi, Yoshinori Umezawa, Osamu Fukuchi, Toshihiro Ito, Hidehisa Saeki, Hidemi Nakagawa. J Dermatol 2014
47
42

Etanercept for the treatment of psoriasis in the elderly.
Giuseppe Militello, Amy Xia, Seth R Stevens, Abby S Van Voorhees. J Am Acad Dermatol 2006
31
42

Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review.
Marieke E C van Winden, Lara S van der Schoot, Mariluz van de L'Isle Arias, Lieke J van Vugt, Juul M P A van den Reek, Peter C M van de Kerkhof, Elke M G J de Jong, Satish F K Lubeek. JAMA Dermatol 2020
6
50

Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Ignacio Garcia-Doval, Gregorio Carretero, Francisco Vanaclocha, Carlos Ferrandiz, Esteban Daudén, Jose-Luis Sánchez-Carazo, Mercé Alsina, Enrique Herrera-Ceballos, Francisco-José Gómez-García, Marta Ferrán,[...]. Arch Dermatol 2012
123
42

Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis.
C Phan, M-L Sigal, E Estève, Z Reguiai, H Barthélémy, N Beneton, F Maccari, M Lahfa, D Thomas-Beaulieu, T Le Guyadec,[...]. J Eur Acad Dermatol Venereol 2016
28
42

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna. Clin Exp Dermatol 2022
15
42


Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D G Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou,[...]. Ann Rheum Dis 2018
119
28

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Andrew Blauvelt, Kim A Papp, Joseph F Merola, Alice B Gottlieb, Nancy Cross, Cynthia Madden, Maggie Wang, Christopher Cioffi, Christopher E M Griffiths. J Am Acad Dermatol 2020
29
28

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
125
28

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
209
28

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Dominique Baeten, Joachim Sieper, Paul Emery, Aimee Readie, Ruvie Martin, Shephard Mpofu, Hanno B Richards. Ann Rheum Dis 2017
159
28

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
567
28


Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Dominique Baeten, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Paul Emery, Désirée van der Heijde, Iain McInnes, Jacob M van Laar, Robert Landewé, Paul Wordsworth,[...]. Lancet 2013
421
28

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
28

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
Mitsumasa Kishimoto, Atsuo Taniguchi, Ayako Fujishige, Shuhei Kaneko, Sibylle Haemmerle, Brian O Porter, Shigeto Kobayashi. Mod Rheumatol 2020
14
28

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
H Marzo-Ortega, J Sieper, A Kivitz, R Blanco, M Cohen, R Martin, A Readie, H B Richards, B Porter. Arthritis Care Res (Hoboken) 2017
61
28

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
Marco Galluzzo, Marina Talamonti, Clara De Simone, Simone D'Adamio, Gaia Moretta, Sara Tambone, Giacomo Caldarola, Maria Concetta Fargnoli, Ketty Peris, Luca Bianchi. Expert Opin Biol Ther 2018
35
28

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Feng Huang, Fei Sun, Wei-Guo Wan, Li-Jun Wu, Ling-Li Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang,[...]. Chin Med J (Engl) 2020
12
28

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, Georg Schett, Jose U Scher, Richard B Warren, Alice B Gottlieb, Deepak Assudani, Kathy Bedford-Rice, Jason Coarse,[...]. Lancet 2020
65
28

Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
Yukie Yamaguchi, Nobumichi Takatsu, Kenji Ootaki, Hidemi Nakagawa. J Dermatol 2020
8
28

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Francisco J Blanco, Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer, Hanno Richards. Arthritis Rheumatol 2017
108
28


Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter. Arthritis Res Ther 2017
111
28


Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic,[...]. J Eur Acad Dermatol Venereol 2018
119
28

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher E M Griffiths, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt. J Am Acad Dermatol 2018
101
28

Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Matteo Megna, Luisa Di Costanzo, Giuseppe Argenziano, Anna Balato, Paola Colasanti, Francesco Cusano, Antonia G Galluccio, Alessio Gambardella, Serena Lembo, Raffaele Mozzillo,[...]. Expert Opin Biol Ther 2019
27
28

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van den Bosch, Evie-Maria Delicha, Zsolt Talloczy, Anke Fierlinger. RMD Open 2019
42
28

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
482
28

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Kim Papp, Craig Leonardi, Alan Menter, Elizabeth H Z Thompson, Cassandra E Milmont, Greg Kricorian, Ajay Nirula, Paul Klekotka. J Am Acad Dermatol 2014
81
28

Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study.
D Thaçi, A Körber, R von Kiedrowski, T Bachhuber, N Melzer, T Kasparek, E Duetting, G Kraehn-Senftleben, U Amon, M Augustin. J Eur Acad Dermatol Venereol 2020
14
28

Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
M Megna, E Cinelli, A Balato, L Gallo, G Fabbrocini. J Eur Acad Dermatol Venereol 2020
9
28



Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
264
28

Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
M Megna, M Napolitano, N Balato, G Monfrecola, A Villani, F Ayala, A Balato. Clin Exp Dermatol 2016
30
28

Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
J J Crowley, R B Warren, J C Cather. J Eur Acad Dermatol Venereol 2019
37
28

Safety concerns with current treatments for psoriasis in the elderly.
Roberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, Gabriella Fabbrocini, Emanuele Scala, Anna Balato. Expert Opin Drug Saf 2020
10
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.